Patents Assigned to Wyeth
  • Chewable tablet containing phenylephrine
    Publication number: 20080026055
    Abstract: A chewable pharmaceutical composition comprising phenylephrine, artificial sweetener, and a substantially aldehyde-free matrix is provided. The composition has phenylephrine stability suitable for a typical commercial product with a two year shelf life. A method of manufacture of the composition and a method of use are also provided.
    Type: Application
    Filed: July 25, 2006
    Publication date: January 31, 2008
    Applicant: Wyeth
    Inventors: Josephine Fubara, Mark Mabry, Aaron Lewis Durr, Angela Taylor, Amanda Alley, David H. Giamalva, Manish Agrawal
  • TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS
    Publication number: 20080027090
    Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.
    Type: Application
    Filed: July 26, 2007
    Publication date: January 31, 2008
    Applicant: WYETH
    Inventors: Matthew A. WILSON, Gregory S. WELMAKER, Eugene J. Trybulski, John A. BUTERA, Ronald L. MAGOLDA
  • BENZOFURANS AS POTASSIUM ION CHANNEL MODULATORS
    Publication number: 20080027049
    Abstract: The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.
    Type: Application
    Filed: July 26, 2007
    Publication date: January 31, 2008
    Applicant: WYETH
    Inventors: Gregory S. WELMAKER, Matthew A. WILSON, Geraldine R. McFARLANE, Joan E. SABALSKI, John A. BUTERA, Eugene J. Trybulski, David R. HERBST
  • 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands
    Publication number: 20080027055
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: August 14, 2007
    Publication date: January 31, 2008
    Applicant: Wyeth
    Inventors: Ping Zhou, Michael Kelly
  • Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
    Publication number: 20080027089
    Abstract: Pharmaceutical composition containing compounds of the following structure, wherein R1-R9, R15, and n are defined herein, are provided. These compositions are useful in treating neurological disorders or complications due to stroke or head injury, and as neuroprotective and neuroregenerative agents.
    Type: Application
    Filed: August 14, 2007
    Publication date: January 31, 2008
    Applicant: Wyeth
    Inventors: Edmund Graziani, Kevin Pong, Jerauld Skotnicki
  • Processes and compounds for the preparation of substituted naphthylindole derivatives
    Patent number: 7323483
    Abstract: The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1(PAI-1). In certain embodiments of the invention, the processes involve reactions that include one or more of an Oppenauer oxidation, a Fischer indole synthesis, a methyl ether cleavage, or coupling a substituted methyltetrazole with a substituted naphthol.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: January 29, 2008
    Assignee: Wyeth
    Inventors: Vladimir A. Dragan, John Richard Potoski, Wayne G. McMahon, Jean Louise Helom, Xinxu Shi
  • 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3)-one derivatives and their use as progesterone receptor modulators
    Patent number: 7323455
    Abstract: This invention provides progesterone receptor modulators having the structure: wherein R1 to R7, X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: January 29, 2008
    Assignee: Wyeth
    Inventors: Puwen Zhang, Jay Edward Wrobel, Eugene Anthony Terefenko, Jeffrey Curtis Kern
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 7323330
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: January 29, 2008
    Assignee: Wyeth
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
    Publication number: 20080021017
    Abstract: The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds having the general structures below: which are useful in contraception and in treating melanoma, osteoporosis, acne, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, adenomyosis, infertility, endometriosis, endometrial cancer, polycystic ovary syndrome, cardiovascular disease, Alzheimer's disease, cognitive decline, central nervous system disorders, central nervous system cancers, leukemia, endometrial ablations, chronic renal disease, chronic hepatic disease, coagulation diseases and disorders, hypocalcemia, hypercalcemia, Paget's disease, osteomalacia, osteohalisteresis, and multiple myeloma.
    Type: Application
    Filed: June 20, 2007
    Publication date: January 24, 2008
    Applicant: Wyeth
    Inventors: Chris Miller, Michael Collini, Bach Tran, Arthur Santilli
  • Mucoadhesive composition
    Publication number: 20080021103
    Abstract: The invention is directed to a topical medicament-containing composition which exhibits excellent bioadhesive properties suitable for application to the human body, including to mucous membranes.
    Type: Application
    Filed: September 21, 2007
    Publication date: January 24, 2008
    Applicant: Wyeth
    Inventors: Khawla ABU-IZZA, Krishna RAMAN, Vincent Li, Sauwaluxana TONGAREE
  • Oxidation process with enhanced safety useful in the manufacture of Moxidectin
    Publication number: 20080021093
    Abstract: The present invention provides a safe and effective process for the selective oxidation of a 5-O-protected-LLF-28249-? compound to the corresponding 23-keto compound of formula I wherein R is a protecting group. The present invention also provides the use of the selective oxidation process in the manufacture of moxidectin.
    Type: Application
    Filed: June 21, 2007
    Publication date: January 24, 2008
    Applicant: Wyeth
    Inventors: Stefania Sapienza, Pasquale Massara, Marco Caraco, Giuseppe Miraglia, Jignesh Patel
  • Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 7320960
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: January 22, 2008
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Susan Ashwell, Reinhardt Bernhard Baudy, Louis John Lombardo
  • Antibody inhibitors of GDF-8 and uses thereof
    Patent number: 7320789
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: January 22, 2008
    Assignee: Wyeth
    Inventors: William J. Dunham, legal representative, Neil M. Wolfman, Denise O'Hara, Monique V. Davies, Geertruida M. Veldman, Kristie Grove Bridges, Lisa-Anne Whittemore, Jane Aghajanian, deceased
  • Processes for the preparation of aryl- and heteroaryl-alkylsulfonyl halides
    Patent number: 7321061
    Abstract: The present invention provides processes for the preparation of arylalkylsulfonyl halides and heteroarylalkylsufonyl halides of Formula I: Ar—R—SO2—X, that are useful as intermediates in the preparation of pharmaceuticals.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: January 22, 2008
    Assignee: Wyeth
    Inventors: Ronald S. Michalak, Mousumi Ghosh, Mahmut Levent
  • Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20080015201
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: June 19, 2007
    Publication date: January 17, 2008
    Applicant: Wyeth
    Inventors: Ronald Bernotas, Yinfa Yan
  • Labeling of rapamycin using rapamycin-specific methylases
    Publication number: 20080014614
    Abstract: A method for rapamycin-specific labeling using rapI, rapM and/or rapQ enzymes is described. Also are methods for generating crude enzyme extracts useful in the method of the invention. Uses of the specifically labeled rapamycin as diagnostic tools are provided.
    Type: Application
    Filed: August 16, 2007
    Publication date: January 17, 2008
    Applicant: Wyeth
    Inventors: Mark Ruppen, Pamela Charbonneau
  • Enhanced stability phenylephrine liquid compositions
    Publication number: 20080014274
    Abstract: An oral, liquid pharmaceutical composition is provided. The composition comprises phenylephrine and substantially aldehyde-free polyethylene glycol. The composition has phenylephrine stability compatible with the stability required for commercial preparations. Optionally, the composition may comprise one or more additional active agents.
    Type: Application
    Filed: July 14, 2006
    Publication date: January 17, 2008
    Applicant: Wyeth
    Inventors: William Bubnis, Stephanie Shield, Gayle P. Hoskovec
  • 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
    Patent number: 7319152
    Abstract: Compounds of formula I or II are provided, wherein R1-R8 are defined herein, and pharmaceutical compositions and kits containing these compounds.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: January 15, 2008
    Assignee: Wyeth
    Inventors: Puwen Zhang, Jeffrey Curtis Kern, Eugene Anthony Terefenko, Eugene John Trybulski
  • Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
    Publication number: 20080009485
    Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.
    Type: Application
    Filed: May 25, 2007
    Publication date: January 10, 2008
    Applicant: Wyeth
    Inventors: Valerie Clerin, Thomas Smith, Katherine Lee
  • Biocatalytic oxidation process useful in the manufacture of moxidectin
    Publication number: 20080009044
    Abstract: The present invention provides a regioselective biological process for the oxidation of the 23-hydroxy group of LLF-28249-? which comprises reacting LL-F28249-? with a biocatalyst that is capable of specifically oxidising the 23-hydroxy group of LL-F28249-?. The present invention also provides the use of the regioselective biological oxidation process in the manufacture of moxidectin.
    Type: Application
    Filed: July 5, 2007
    Publication date: January 10, 2008
    Applicant: Wyeth
    Inventors: Daniel Howard Cohen, Thomas Gerard Cullen, Jignesh Patel, Michael Joseph O'Neill